Target therapies in lung cancer

Journal of Biomedicine and Biotechnology

Volumn 2011, Issue , 2011, Pages

  Bearz, A ^a   Berretta, M ^a   Lleshi, A ^a   Tirelli, U ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ANGIOGENIC FACTOR; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CIXUTUMUMAB; CRIZOTINIB; DALOTUZUMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR; ERLOTINIB; FIGITUMUMAB; GEFITINIB; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR; LAPATINIB; PACLITAXEL; PANITUMUMAB; PEMETREXED; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; SORAFENIB; SUNITINIB; TIVANTINIB; TYROSINE KINASE RECEPTOR; UNINDEXED DRUG; VADIMEZAN; VANDETANIB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL SURVIVAL; DISEASE COURSE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; ONCOGENE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TOXICITY; ANIMAL; LUNG TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); SIGNAL TRANSDUCTION; VASCULARIZATION;

ANIMALS; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 79959330502     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2011/921231     Document Type: Review

References (51)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., Thun M. J., Cancer statistics, 2010 CA: A Cancer Journal for Clinicians 2010 60 5 277 300
2. Spira A., Ettinger D. S., Multidisciplinary management of lung cancer New England Journal of Medicine 2004 350 4 379 392 (Pubitemid 38101633)
3. Salgia R., Skarin A. T., Molecular abnormalities in lung cancer Journal of Clinical Oncology 1998 16 3 1207 1217 (Pubitemid 28108759)
4. Folkman J., Tumor angiogenesis: therapeutic implications New England Journal of Medicine 1971 285 21 1182 1186
5. Senger D. R., Galli S. J., Dvorak A. M., Perruzzi C. A., Susan Harvey V., Dvorak H. F., Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid Science 1983 219 4587 983 985
6. Ferrara N., Gerber H. P., LeCouter J., The biology of VEGF and its receptors Nature Medicine 2003 9 6 669 676 (Pubitemid 36749215)
7. Olofsson B., Korpelainen E., Pepper M. S., Mandriota S. J., Aase K., Kumar V., Gunji Y., Jeltsch M. M., Shibuya M., Alitalo K., Eriksson U., Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells Proceedings of the National Academy of Sciences of the United States of America 1998 95 20 11709 11714 (Pubitemid 28460479)
8. Paavonen K., Puolakkainen P., Jussila L., Jahkola T., Alitalo K., Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing American Journal of Pathology 2000 156 5 1499 1504 (Pubitemid 30646689)
9. He Y., Rajantie I., Pajusola K., Jeltsch M., Holopainen T., Yla-Herttuala S., Harding T., Jooss K., Takahashi T., Alitalo K., Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels Cancer Research 2005 65 11 4739 4746 (Pubitemid 40740810)
10. Ferrara N., Vascular endothelial growth factor: basic science and clinical progress Endocrine Reviews 2004 25 4 581 611 (Pubitemid 39099316)
11. Semenza G. L., Targeting HIF-1 for cancer therapy Nature Reviews Cancer 2003 3 10 721 732 (Pubitemid 37328811)
12. Ferrara N., Kerbel R. S., Angiogenesis as a therapeutic target Nature 2005 438 7070 967 974 (Pubitemid 43093963)
13. Podar K., Anderson K. C., The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications Blood 2005 105 4 1383 1395 (Pubitemid 40223651)
14. Johnson D. H., Fehrenbacher L., Novotny W. F., Herbst R. S., Nemunaitis J. J., Jablons D. M., Langer C. J., DeVore R. F., Gaudreault J., Damico L. A., Holmgren E., Kabbinavar F., Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer Journal of Clinical Oncology 2004 22 11 2184 2191 (Pubitemid 41095154)
15. Sandler A., Gray R., Perry M. C., Brahmer J., Schiller J. H., Dowlati A., Lilenbaum R., Johnson D. H., Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer New England Journal of Medicine 2006 355 24 2542 2550 (Pubitemid 44917502)
16. Reck M., Von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., Leighl N., Mezger J., Archer V., Moore N., Manegold C., Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL Journal of Clinical Oncology 2009 27 8 1227 1234
17. Johnson B. E., Ryan A. J., Heymach J., Tumor biomarkers analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC Journal of Clinical Oncology 2010 28 15 542s. Proceedings of ASCO Annual Meeting, abstract 7516
18. De Boer R., Arrieta O., Gottfried M., Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL) Journal of Clinical Oncology 2009 27, supplement 15s. Proceedings of ASCO Annual Meeting, abstract 8010
19. Natale R. B., Thongprasert S., Greco F. A., Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST) Journal of Clinical Oncology 2009 27, supplement 15s. Proceedings of ASCO Annual Meeting, abstract 8009
20. Lee J., Hirsh V., Park K., Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): a randomized, double-blind phase III trial (ZEPHYR) Journal of Clinical Oncology 2010 28 15s. Proceedings of ASCO Annual Meeting, abstract 7525
21. http://www.clinicaltrials.gov/
22. Scagliotti G. V., Krakowski M., Szczesna A., Sunitinib in combination with Erlotinib for the treatment of advanced/metastatic non-small cell lung cancer: a phase III study Annals Of Oncology 2010 21 viii1 viii2. LBA no. 6
23. Gatzmeier U., Eisen T., Santoro A., Sorafenib + Gemcitabine/cisplatin (GC) vs GC alone in the first-line treatment of advanced non-small cell lung cancer: phase III NSCLC research experience utilizing sorafenib. Nexus trial Annals of Oncology 2010 21 viii7. LBA no. 15
24. Cohen S., The stimulation of epidermal proliferation by a specific protein (EGF) Developmental Biology 1965 12 3 394 407
25. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J. Y., Nishiwaki Y., Vansteenkiste J., Kudoh S., Rischin D., Eek R., Horai T., Noda K., Takata I., Smit E., Averbuch S., Macleod A., Feyereislova A., Dong R. P., Baselga J., Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer Journal of Clinical Oncology 2003 21 12 2237 2246 (Pubitemid 46621858)
26. Kris M. G., Natale R. B., Herbst R. S., Lynch T. J., Prager D., Belani C. P., Schiller J. H., Kelly K., Spiridonidis H., Sandler A., Albain K. S., Cella D., Wolf M. K., Averbuch S. D., Ochs J. J., Kay A. C., Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial Journal of the American Medical Association 2003 290 16 2149 2158 (Pubitemid 37432975)
27. Lynch T. J., Bell D. W., Sordella R., Gurubhagavatula S., Okimoto R. A., Brannigan B. W., Harris P. L., Haserlat S. M., Supko J. G., Haluska F. G., Louis D. N., Christiani D. C., Settleman J., Haber D. A., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib New England Journal of Medicine 2004 350 21 2129 2139 (Pubitemid 38637993)
28. Paez J. G., Jnne P. A., Lee J. C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F. J., Lindeman N., Boggon T. J., Naoki K., Sasaki H., Fujii Y., Eck M. J., Sellers W. R., Johnson B. E., Meyerson M., EGFR mutations in lung, cancer: correlation with clinical response to gefitinib therapy Science 2004 304 5676 1497 1500 (Pubitemid 38720929)
29. Thatcher N., Chang A., Parikh P., Pereira J. R., Ciuleanu T., Von Pawel J., Thongprasert S., Tan E. H., Pemberton K., Archer V., Carroll K., Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 2005 366 9496 1527 1537 (Pubitemid 41540110)
30. Shepherd F. A., Pereira J. R., Ciuleanu T., Eng H. T., Hirsh V., Thongprasert S., Campos D., Maoleekoonpiroj S., Smylie M., Martins R., Van Kooten M., Dediu M., Findlay B., Tu D., Johnston D., Bezjak A., Clark G., Santabrbara P., Seymour L., Erlotinib in previously treated non-small-cell lung cancer New England Journal of Medicine 2005 353 2 123 132 (Pubitemid 41058344)
31. Mok T. S., Wu Y. L., Thongprasert S., Yang C. H., Chu DA. T., Saijo N., Sunpaweravong P., Han B., Margono B., Ichinose Y., Nishiwaki Y., Ohe Y., Yang J. J., Chewaskulyong B., Jiang H., Duffield E. L., Watkins C. L., Armour A. A., Fukuoka M., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma New England Journal of Medicine 2009 361 10 947 957
32. Fukuoka M., Wo Y., Thongprasert S., Biomarker analyses from a phase III, randomized, open-label, first-line study of Gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS) Journal of Clinical Oncology 2009 27 15 408s. Proceedings of ASCO Annual Meeting, abstract no 8006
33. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., Seto T., Satouchi M., Tada H., Hirashima T., Asami K., Katakami N., Takada M., Yoshioka H., Shibata K., Kudoh S., Shimizu E., Saito H., Toyooka S., Nakagawa K., Fukuoka M., Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial The Lancet Oncology 2010 11 2 121 128
34. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., Gemma A., Harada M., Yoshizawa H., Kinoshita I., Fujita Y., Okinaga S., Hirano H., Yoshimori K., Harada T., Ogura T., Ando M., Miyazawa H., Tanaka T., Saijo Y., Hagiwara K., Morita S., Nukiwa T., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR New England Journal of Medicine 2010 362 25 2380 2388
35. Yang C. H., Fukuoka M., Mok T. S., Final overall survival results from a phase III, randomised, open-label, first-line study of gefitinib v carboplatin/paclitaxel in clinically selected patients with advanced non small cell lung cancer (NSCLC) in Asia (IPASS) Annals of Oncology 2010 21 viii1 viii12. LBA no. 2
36. Pirker R., Pereira J. R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., Vynnychenko I., Park K., Yu C. T., Ganul V., Roh J. K., Bajetta E., O'Byrne K., de Marinis F., Eberhardt W., Goddemeier T., Emig M., Gatzemeier U., Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial The Lancet 2009 373 9674 1525 1531
37. Khambata-Ford S., K-RAS mutations and EGFR-related markers as potential predictors of cetuximab benefit in first line advanced NSCLC:results from the BMS 099 study Proceedings of the Chicago Multidisciplinary Symposium in Thoracic Oncology 2008 Chicago, Ill, USA
38. Yang C., Shih J., Su W., A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR/HER1 mutations (LUX-LUNG 2) Annals of Oncology 2010 21 supplement 8 viii123. abstract 367PD
39. Ding L., Getz G., Wheeler D. A., Mardis E. R., McLellan M. D., Cibulskis K., Sougnez C., Greulich H., Muzny D. M., Morgan M. B., Fulton L., Fulton R. S., Zhang Q., Wendl M. C., Lawrence M. S., Larson D. E., Chen K., Dooling D. J., Sabo A., Hawes A. C., Shen H., Jhangiani S. N., Lewis L. R., Hall O., Zhu Y., Mathew T., Ren Y., Yao J., Scherer S. E., Clerc K., Metcalf G. A., Ng B., Milosavljevic A., Gonzalez-Garay M. L., Osborne J. R., Meyer R., Shi X., Tang Y., Koboldt D. C., Lin L., Abbott R., Miner T. L., Pohl C., Fewell G., Haipek C., Schmidt H., Dunford-Shore B. H., Kraja A., Crosby S. D., Sawyer C. S., Vickery T., Sander S., Robinson J., Winckler W., Baldwin J., Chirieac L. R., Dutt A., Fennell T., Hanna M., Johnson B. E., Onofrio R. C., Thomas R. K., Tonon G., Weir B. A., Zhao X., Ziaugra L., Zody M. C., Giordano T., Orringer M. B., Roth J. A., Spitz M. R., Wistuba I. I., Ozenberger B., Good P. J., Chang A. C., Beer D. G., Watson M. A., Ladanyi M., Broderick S., Yoshizawa A., Travis W. D., Pao W., Province M. A., Weinstock G. M., Varmus H. E., Gabriel S. B., Lander E. S., Gibbs R. A., Meyerson M., Wilson R. K., Somatic mutations affect key pathways in lung adenocarcinoma Nature 2008 455 7216 1069 1075
40. Ahrendt S. A., Decker P. A., Alawi E. A., Zhu Y. R., Sanchez-Cespedes M., Yang S. C., Haasler G. B., Kajdacsy-Balla A., Demeure M. J., Sidransky D., Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung Cancer 2001 92 6 1525 1530 (Pubitemid 32947838)
41. Hunt J. D., Strimas A., Martin J. E., Eyer M., Haddican M., Luckett B. G., Ruiz B., Axelrad T. W., Backes W. L., Fontham E. T.H., Differences in KRAS mutation spectrum in lung cancer cases between African Americans and Caucasians after occupational or environmental exposure to known carcinogens Cancer Epidemiology Biomarkers and Prevention 2002 11 11 1405 1412 (Pubitemid 35340377)
42. Roberts P. J., Der C. J., Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 2007 26 22 3291 3310 (Pubitemid 46763022)
43. Riely G. J., Kris M. G., Rosenbaum D., Marks J., Li A., Chitale D. A., Nafa K., Riedel E. R., Hsu M., Pao W., Miller V. A., Ladanyi M., Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma Journal of Clinical Oncology 2008 26, supplement 425s. abstract 8006
44. Johnson M. L., Sima C., Paik P. K., Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinoma Journal of Clinical Oncology 2010 28 15 15s. Proceedings of ASCO Annual Meeting, abstract 7541
45. Jackman D. M., Miller V. A., Cioffredi L.-A., Yeap B. Y., Jnne P. A., Riely G. J., Ruiz M. G., Giaccone G., Sequist L. V., Johnson B. E., Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials Clinical Cancer Research 2009 15 16 5267 5273
46. Cooper C. S., Park M., Blair D. G., Molecular cloning of a new transforming gene from a chemically transformed human cell line Nature 1984 311 5981 29 33 (Pubitemid 14065275)
47. Schiller J. H., Arkerley W. L., Brugger W., Results from ARQ 197209: a global randomized placebo-controlled phase II clinical trial of Erlotinib plus ARQ 197 versus Erlotinib plus placebo in previously treated EGFR inhibitor-nave patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) Journal of Clinical Oncology 2010 28 15S 539s. Proceedings of ASCO Annual Meeting, LBA 7502
48. Kwak E. L., Bang Y.-J., Camidge D. R., Shaw A. T., Solomon B., Maki R. G., Ou S.-H.I., Dezube B. J., Jnne P. A., Costa D. B., Varella-Garcia M., Kim W.-H., Lynch T. J., Fidias P., Stubbs H., Engelman J. A., Sequist L. V., Tan W., Gandhi L., Mino-Kenudson M., Wei G. C., Shreeve S. M., Ratain M. J., Settleman J., Christensen J. G., Haber D. A., Wilner K., Salgia R., Shapiro G. I., Clark J. W., Iafrate A. J., Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer New England Journal of Medicine 2010 363 18 1693 1703
49. Yee D., Targeting insulin-like growth factor pathways British Journal of Cancer 2006 94 4 465 468 (Pubitemid 43289747)
50. Gualberto A., Hixon M. L., Karp D. D., Li D., Green S., Dolled-Filhart M., Paz-Ares L. G., Novello S., Blakely J., Langer C. J., Pollak M. N., Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab British Journal of Cancer 2011 104 1 68 74
51. Jassem J., Langer C. J., Karp D. D., Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) Journal of Clinical Oncology 2010 28 15. Proceedings of ASCO Annual Meeting, abstract 7500